Evidence map›Paper›PMID 41769411›Full record

ArticlePeerJ2026

Proteomic landscape of colorectal cancer liver metastasis: molecular signatures and novel therapeutic targets.

Hongyuan Shen, Jia Li, Guoqing Wang, Xiangyu Su, Zhigang Zhang, Jinjun Shi

Abstract read
In one paragraph

Article in PeerJ, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors.

Hongyuan ShenDepartment of Ultrasound, Zhongda Hospital Southeast University, Nan Jing, Jiang Su, China.
Jia LiDepartment of Ultrasound, Zhongda Hospital Southeast University, Nan Jing, Jiang Su, China.
Guoqing WangDepartment of Pathology, Zhongda Hospital Southeast University, Nan Jing, Jiang Su, China.
Xiangyu SuDepartment of Oncology, Zhongda Hospital Southeast University, Nan Jing, Jiang Su, China.
Zhigang ZhangDepartment of Gastrointestinal Surgery, Zhongda Hospital Southeast University, Nan Jing, Jiang Su, China.
Jinjun ShiDepartment of Ultrasound, Zhongda Hospital Southeast University, Nan Jing, Jiang Su, China.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Background: Liver metastasis accounts for most deaths in colorectal cancer patients, but we still lack a clear understanding of how this devastating process unfolds at the molecular level. Identifying these mechanisms could lead to better ways to predict and treat metastatic disease. Methods: We performed proteomic analysis on 38 tissue samples, including benign adenomas, primary colorectal tumors, and liver metastases, to map the molecular changes that drive cancer spread to the liver. Results: We found striking differences in protein expression patterns across tissue types. Primary tumors showed massive protein changes compared to normal tissue (nearly 1,900 alterations), but liver metastases were surprisingly selective in their modifications (just 89 unique changes from primary tumors). This specificity indicates that liver colonization depends on precise molecular adjustments rather than random cellular disruption. The proteins involved in metastasis fell into three main categories: tissue restructuring to support tumor growth, mechanisms to avoid immune detection, and blood clotting factors that help cancer cells establish themselves in the liver. We validated three biomarkers with clinical potential: HDHD3 shows promise for detecting existing metastases, while OLFM4 and ZNF34 can help identify primary tumors at high risk for spreading. Conclusions: Our work reveals that colorectal cancer liver metastasis involves targeted molecular changes rather than widespread cellular chaos. The biomarkers we identified could improve early detection of metastatic risk and guide more personalized treatment decisions for patients.

Indexed as

Biomarkers, TumorColorectal NeoplasmsLiver NeoplasmsProteomicsFemaleHumansMaleBiomarkers, TumorBiomarkersColorectal cancer (CRC)Extracellular matrix (ECM)Immune evasionLiver metastasisProteomic analysis

Identifiers

PMID41769411
PMCPMC12939789

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.